Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease
Tóm tắt
Digestive tract damage during graft-versus-host reaction (GVHR) causes high morbidity and mortality. Diagnosis is often late because biopsies are performed when clinical signs are severe and pathologic markers of early inflammatory lesions are lacking. Eosinophils are inflammatory cells, cytotoxic in vitro to digestive epithelium; they are found in biopsy specimens taken during acute flare-ups of inflammatory bowel disease. We performed systematic duodenal biopsies immediately after digestive symptoms occurred and found a digestive GVHR incidence of 73.1% (n = 93), higher than that found when digestive biopsies were performed immediately after severe clinical signs. Eosinophils were only present when there were histologic signs of GVHR; eosinophil presence correlated with GVHR severity. Electron microscopy with immunogold staining showed pathologic signs of in situ eosinophil activation, such as cytoplasmic granule alterations, and eosinophil peroxidase release in all patients. Interleukin-5 presence in activated eosinophils suggests eosinophil recruitment in digestive GVHR is an autocrine mechanism. Eosinophil density also correlated with GVHR severity, whether in acute or chronic clinical phases. Tissue eosinophils could thus be a marker of acute inflammatory flare-ups in GVHR. Systematic duodenal biopsy performed at the onset of digestive symptoms should allow early GVHR detection, and pathologic signs of GVHR, together with eosinophil density, might help modulate immunosuppressive therapy.
Tài liệu tham khảo
Weller, 1991, The immunobiology of eosinophils., N Engl J Med., 324, 1110, 10.1056/NEJM199104183241607
Watanabe, 1999, The degranulation of eosinophils by cell lysis., Eur Microscop Analysis., 60, 21
Yamaguchi, 1988, Highly purified murine interleukin-5 (IL-5) stimulates eosinophil function and prolongs in vitro survival., J Exp Med., 167, 1737, 10.1084/jem.167.5.1737
Yamaguchi, 1988, Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors., J Exp Med., 167, 43, 10.1084/jem.167.1.43
Lopez, 1988, Recombinant human interleukin 5 is a selective activator of human eosinophil function., J Exp Med., 167, 219, 10.1084/jem.167.1.219
Vandezande, 1999, Interleukin-5 immunoreactivity and mRNA expression in gut mucosa from patients with food allergy., Clin Exp Allergy., 29, 652, 10.1046/j.1365-2222.1999.00511.x
Wallaert, 1995, Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma., J Exp Med., 182, 1897, 10.1084/jem.182.6.1897
Desreumaux, 1993, Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases., Blood., 82, 1553, 10.1182/blood.V82.5.1553.1553
Clutterbuck, 1989, Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cells: comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF., Blood., 73, 1504, 10.1182/blood.V73.6.1504.1504
Garcia-Zepeda, 1996, Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia., Nat Med., 2, 449, 10.1038/nm0496-449
Li, 1998, Th2-induced eotaxin expression and eosinophilia coexist with Th1 responses at the effector stage of lung inflammation., J Immunol., 161, 3128, 10.4049/jimmunol.161.6.3128
Guo, 1999, Eotaxin expression in Sephadex-induced lung injury in rats., Am J Pathol., 155, 2001, 10.1016/S0002-9440(10)65519-8
Mishra, 2000, Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin., Blood., 96, 1538, 10.1182/blood.V96.4.1538
Dvorak, 1980, Ultrastructural evidence for release of major basic protein-containing crystalline cores of eosinophil granules in vitro: cytotoxic potential in Crohn's disease., J Immunol., 125, 460, 10.4049/jimmunol.125.1.460
Colombel, 1992, Activated eosinophils in adult celiac disease: evidence for a local release of major basic protein., Gut., 33, 1190, 10.1136/gut.33.9.1190
Dubucquoi, 1995, Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease., Gut., 37, 242, 10.1136/gut.37.2.242
Desreumaux, 1997, Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease., Gastroenterology., 113, 118, 10.1016/S0016-5085(97)70116-1
Dvorak, 1993, Ultrastructural identification of exocytosis of granules from human gut eosinophils in vivo., Arch Allergy Immunol., 102, 33, 10.1159/000236548
Desreumaux, 1998, Similar IL-5, IL-3, and GM-CSF syntheses by eosinophils in the jejunal mucosal of patients with celiac disease and dermatitis herpetiformis., Clin Immunol Immunopathol., 88, 14, 10.1006/clin.1997.4494
Hällgren, 1989, Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents., Am J Med., 86, 56, 10.1016/0002-9343(89)90230-1
Foster, 1989, Blood and graft eosinophilia as predictors of rejection in human liver transplantation., Transplantation., 47, 72, 10.1097/00007890-198901000-00016
Hughes, 1998, Monitoring eosinophil activation and liver function after liver transplantation., Transplantation., 65, 1334, 10.1097/00007890-199805270-00009
De Groen, 1994, The eosinophil as an effector cell of the immune response during hepatic allograft rejection., Hepatology., 20, 654, 10.1002/hep.1840200317
Hällgren, 1991, Activated eosinophil infiltration and deposits of eosinophil cationic protein in renal allograft rejection., Nephron., 59, 266, 10.1159/000186563
Wir, 1986, The prognostic value of the eosinophil in acute renal allograft rejection., Transplantation., 41, 709, 10.1097/00007890-198606000-00008
Ben-Ari, 1996, Prognostic value of eosinophils for therapeutic response in severe acute hepatic allograft rejection., Transplant Proc., 28, 3624
Galliam, 1996, Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versus-host disease., J Invest Dermatol., 107, 377, 10.1111/1523-1747.ep12363361
MacDonald, 1992, Cell-mediated immune injury in the intestine., Gastroenterol Clin North Am., 21, 367, 10.1016/S0889-8553(21)00036-4
Guy-Grand, 1986, Gut injury in mouse graft-versus-host disease., J Clin Invest., 77, 1584, 10.1172/JCI112474
Hill, 1997, Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines., Blood., 90, 3204, 10.1182/blood.V90.8.3204
Hill, 2000, The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: relation for the use of cytokine shields in allogeneic bone marrow transplantation., Blood., 95, 2754, 10.1182/blood.V95.9.2754.009k25_2754_2759
Nikolic, 2000, Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets., J Clin Invest., 105, 1289, 10.1172/JCI7894
Bombi, 1995, Assessment of histopathologic changes in the colonic biopsy in acute graft-versus-host disease., Am J Clin Pathol., 103, 690, 10.1093/ajcp/103.6.690
Spencer, 1986, Diffuse intestinal ulceration after marrow transplantation: a clinicopathologic study of 13 patients., Hum Pathol., 17, 621, 10.1016/S0046-8177(86)80135-6
Snover, 1985, A histolopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation., Hum Pathol., 16, 387, 10.1016/S0046-8177(85)80232-X
Sviland, 1988, Histological features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation., J Clin Pathol., 41, 148, 10.1136/jcp.41.2.148
Weisdorf, 1990, Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy., Blood., 76, 624, 10.1182/blood.V76.3.624.624
Rumi, 1998, Immunophenotypic profile of peripheral blood eosinophils in acute graft-vs.-host disease., Exp Hematol., 26, 170
Kalaycioglu, 1994, Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen., Bone Marrow Transplant., 14, 113
Janin, 1994, Faciitis in chronic graft-versus-host disease., Ann Intern Med., 120, 993, 10.7326/0003-4819-120-12-199406150-00004
Coudert, 2000, Lethal host-versus-graft disease and hypereosinophilia in the absence of MHC I–T-cell interactions., J Clin Invest., 105, 1125, 10.1172/JCI9243
Glucksberg, 1974, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors., Transplantation., 18, 295, 10.1097/00007890-197410000-00001
Sale, 1979, Gastrointestinal graft-versus-host disease in man: a clinicopathological study of the rectal biopsy., Am J Surg Pathol., 3, 291, 10.1097/00000478-197908000-00001
Epstein, 1980, The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients., Gastroenterology., 78, 764, 10.1016/0016-5085(80)90681-2
Washington, 1997, Gastric graft-versus-host disease: a blinded histologic study., Am J Surg Pathol., 2, 1037, 10.1097/00000478-199709000-00008
Roth, 1981, Enhancement of structural preservation and immunocytochemical staining in low temperature embedded pancreatic tissue., J Histochem Cytochem., 29, 663, 10.1177/29.5.6166664
Roy, 1991, Simultaneous upper and lower endoscopy in the diagnosis of intestinal graft-versus-host disease., Transplantation., 51, 642, 10.1097/00007890-199103000-00019
Leiferman, 1995, Hypereosinophilic syndrome., Semin Dermatol., 14, 122, 10.1016/S1085-5629(05)80007-0
Desreumaux, 1996, Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis., Gastroenterology., 110, 768, 10.1053/gast.1996.v110.pm8608886
Eversole, 2000, Changes in the morphology and the distribution of rat intestinal eosinophils during infection with the nematode Nippostrongylus brasiliensis., Lab Invest., 79, 785
Egesten, 1986, Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique., J Histochem Cytochem., 34, 1399, 10.1177/34.11.3772075
Khalife, 1986, Role of specific IgE antibodies in peroxidase (EPO) release from human eosinophils., J Immunol., 137, 1659, 10.4049/jimmunol.137.5.1659
Dent, 1990, Eosinophilia in transgenic mice expressing interleukin 5., J Exp Med., 172, 1425, 10.1084/jem.172.5.1425
Rothenberg, 1991, Eosinophilia., N Engl J Med., 338, 1592, 10.1056/NEJM199805283382206
Dubucquoi, 1994, Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion., J Exp Med., 179, 703, 10.1084/jem.179.2.703
Desreumaux, 1992, Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosae of patients with coeliac disease., J Exp Med., 175, 293, 10.1084/jem.175.1.293
Druilhe, 1996, Fas-mediated apoptosis in cultured human eosinophils., Blood., 87, 2822, 10.1182/blood.V87.7.2822.bloodjournal8772822
Wallen, 1991, Glucocorticoids inhibit cytokine-mediated eosinophil survival., J Immunol., 147, 3490, 10.4049/jimmunol.147.10.3490
Taha, 1999, Eotaxin and monocyte chemotactic protein-4 mRNA expression in small airways of asthmatic and nonathmatic individuals., J Allergy Clin Immunol., 103, 476, 10.1016/S0091-6749(99)70474-4
Heath, 1997, Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody., J Clin Invest., 99, 178, 10.1172/JCI119145